

Incidence in Norway 2015


•5061 menn

Deaths in Norway 2015

•1045 menn

2.9% lifetime risk of dying from prostate cancer

(Ries et al. SEER Cancer statistics 1975-2004)



The prostate cancer challenge

Diagnosis is challenging

 good clinical tools are limited

Underdiagnosis


Overdiagnosis

Treatment side-effects


Life threatening?







The prostate cancer challenge



Diagnosis is challenging

 good clinical tools are limited

Underdiagnosis
Overdiagnosis
Treatment side-effects

Identify the life threatening prostate cancers

Systematic review of 29 autopsy studies (2015)



IJC International Journal of Cancer

Prevalence of incidental prostate cancer: A systematic review of autopsy studies

Katy J.L. Bell^{1,2}, Chris Del Mar¹, Gordon Wright³, James Dickinson^{4,5} and Paul Glasziou¹

Prostate cancer screening may detect nonprogressive cancers, leading to overdiagnosis and overtreatment. The potential for overdiagnosis can be assessed from the reservoir of prostate cancer in autopsy studies that report incidental prostate cancer rates in men who died of other causes. We aimed to estimate the age-specific incidental cancer prevalence from all published

30 years old> 4%
50 years old>30%
60 years old>40%
80 years old>60%
90 years old>90%



¹Centre for Research in Evidence Based Practice (CREBP), Faculty of Health Sciences and Medicine, Bond University, Gold Coast, Qld, Australia

² Screening and Diagnostic Test Evaluation Program (STEP), School of Public Health, University of Sydney

³ Faculty of Health Sciences and Medicine, Bond University, Gold Coast, Qld, Australia

⁴ Department of Family Medicine, Faculty of Medicine, University of Calgary, Calgary, AB, Canada

⁵Department of Community Health Sciences, Faculty of Medicine, University of Calgary, Calgary, AB, Canada







'Tissue is the issue':
a multi-omics approach to improve
prostate cancer diagnosis

PI: May-Britt Tessem

Associate Professor/Research Scientist

Department of Circulation and Medical Imaging

NTNU, Trondheim







How to obtain the correct diagnosis?





multi-level information on molecular signatures of each cancer patient

Key idea:


multi-omics technology and histopathology on the same prostate tissue sample

Unique resources:

High quality largescale tissue biobanks

Human tissue biobanks

available for ERC project




1: Prostatectomy biopsies N=1000



2: Prostatectomy tissue slices N~1000




3: MR guided biopsies N=100





Key methodology and collaborations



THE ARCTIC UNIVERSITY







